Wall Street brokerages forecast that Sientra Inc (NASDAQ:SIEN) will report $16.27 million in sales for the current fiscal quarter, according to Zacks. Three analysts have made estimates for Sientra’s earnings. The highest sales estimate is $16.50 million and the lowest is $16.10 million. Sientra reported sales of $9.82 million in the same quarter last year, which indicates a positive year over year growth rate of 65.7%. The business is scheduled to report its next quarterly earnings report after the market closes on Tuesday, November 6th.
On average, analysts expect that Sientra will report full-year sales of $67.97 million for the current year, with estimates ranging from $67.10 million to $68.70 million. For the next financial year, analysts anticipate that the firm will report sales of $95.93 million, with estimates ranging from $93.30 million to $97.90 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research analysts that cover Sientra.
Sientra (NASDAQ:SIEN) last issued its earnings results on Tuesday, August 7th. The medical instruments supplier reported ($0.73) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.69) by ($0.04). Sientra had a negative net margin of 131.16% and a negative return on equity of 151.47%. The company had revenue of $17.55 million during the quarter, compared to analyst estimates of $15.30 million.
In other news, CEO Jeffrey M. Nugent sold 1,852 shares of Sientra stock in a transaction that occurred on Friday, August 31st. The stock was sold at an average price of $24.90, for a total transaction of $46,114.80. Following the sale, the chief executive officer now owns 297,999 shares of the company’s stock, valued at $7,420,175.10. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 31.00% of the company’s stock.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. raised its holdings in shares of Sientra by 94.3% during the second quarter. BlackRock Inc. now owns 1,490,587 shares of the medical instruments supplier’s stock valued at $29,081,000 after buying an additional 723,279 shares during the last quarter. Gilder Gagnon Howe & Co. LLC raised its holdings in Sientra by 29.8% during the second quarter. Gilder Gagnon Howe & Co. LLC now owns 1,373,007 shares of the medical instruments supplier’s stock worth $26,787,000 after purchasing an additional 315,408 shares in the last quarter. Janus Henderson Group PLC bought a new stake in Sientra during the second quarter worth approximately $20,375,000. Millennium Management LLC raised its holdings in Sientra by 93.4% during the second quarter. Millennium Management LLC now owns 858,206 shares of the medical instruments supplier’s stock worth $16,744,000 after purchasing an additional 414,418 shares in the last quarter. Finally, Waddell & Reed Financial Inc. bought a new stake in Sientra during the second quarter worth approximately $15,035,000. 89.22% of the stock is currently owned by institutional investors.
SIEN stock traded down $1.81 during midday trading on Friday, reaching $19.24. The company had a trading volume of 405,100 shares, compared to its average volume of 414,730. The company has a quick ratio of 2.63, a current ratio of 3.06 and a debt-to-equity ratio of 0.27. Sientra has a fifty-two week low of $8.79 and a fifty-two week high of $26.79. The company has a market cap of $630.24 million, a P/E ratio of -6.82 and a beta of -0.78.
Sientra Company Profile
Sientra, Inc, a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names.
See Also: Why Dividend Stocks May Be Right for You
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with MarketBeat.com's FREE daily email newsletter.